Drug intelligence / Profile preview

Mapreg Post-Traumatic recovery program

Development stage: Preclinical
Lead developer: Mapreg
Modality: Small Molecules

Overview

Mapreg's Post-Traumatic recovery program involves a blood-brain barrier (BBB)-penetrant small molecule ligand targeting microtubule-associated protein 2 (MAP-2). MAP-2 is a protein primarily enriched in dendrites and serves as a critical marker for synaptic plasticity. Following traumatic brain injury, MAP-2 levels and distribution are often altered, impacting neuronal structural integrity. This therapeutic candidate is designed to modulate the MAP-2/microtubule interaction to facilitate neuroplasticity and functional recovery. It is currently in the preclinical stage of development as part of Mapreg's pipeline of neuroplastogen therapeutics.

Other names: Post-Traumatic recovery programMapreg MAP-2 small molecule

Beyond the preview

Go deeper on Mapreg Post-Traumatic recovery program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mapreg Post-Traumatic recovery program.

Explore the full profile